Despite its rarity, infliximab-related hepatitis constitutes a cutting edge and challenging problem. In December 2004, a drug warning was issued by the Food and Drug Administration to alert healthcare professionals to the risk of hepatotoxicity in course of infliximab therapy. Subsequently, several reports of probable infliximab hepatitis have been published and interest is growing in trying to elucidate the impact of these events on clinical practice. After discussing our case report, the main characteristics of infliximab-mediated liver injury are analyzed, coupled with a review of the medical literature. Infliximab seems to provoke both immunomediated and a direct liver injury, but how this latter happens remains unclear. Moreover, infliximab immunomediated liver dysfunction resembles that of autoimmune hepatitis type I, with elevation of antinuclear, anti-smooth muscle, anti-double-strand DNA antibodies, and a clear preference for female sex. Finally, a flow chart is proposed with the purpose to help clinicians in the management of patients who develop signs of liver dysfunction during treatment with infliximab.

Infliximab-related hepatitis: discussion of a case and review of the literature / Mancini, S; Amorotti, E; Vecchio, S; PONZ DE LEON, Maurizio; Roncucci, Luca. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - ELETTRONICO. - 5:3(2010), pp. 193-200. [10.1007/s11739-009-0342-4]

Infliximab-related hepatitis: discussion of a case and review of the literature.

PONZ DE LEON, Maurizio;RONCUCCI, Luca
2010

Abstract

Despite its rarity, infliximab-related hepatitis constitutes a cutting edge and challenging problem. In December 2004, a drug warning was issued by the Food and Drug Administration to alert healthcare professionals to the risk of hepatotoxicity in course of infliximab therapy. Subsequently, several reports of probable infliximab hepatitis have been published and interest is growing in trying to elucidate the impact of these events on clinical practice. After discussing our case report, the main characteristics of infliximab-mediated liver injury are analyzed, coupled with a review of the medical literature. Infliximab seems to provoke both immunomediated and a direct liver injury, but how this latter happens remains unclear. Moreover, infliximab immunomediated liver dysfunction resembles that of autoimmune hepatitis type I, with elevation of antinuclear, anti-smooth muscle, anti-double-strand DNA antibodies, and a clear preference for female sex. Finally, a flow chart is proposed with the purpose to help clinicians in the management of patients who develop signs of liver dysfunction during treatment with infliximab.
2010
5
3
193
200
Infliximab-related hepatitis: discussion of a case and review of the literature / Mancini, S; Amorotti, E; Vecchio, S; PONZ DE LEON, Maurizio; Roncucci, Luca. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - ELETTRONICO. - 5:3(2010), pp. 193-200. [10.1007/s11739-009-0342-4]
Mancini, S; Amorotti, E; Vecchio, S; PONZ DE LEON, Maurizio; Roncucci, Luca
File in questo prodotto:
File Dimensione Formato  
Infliximab-related hepatitis.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 344.41 kB
Formato Adobe PDF
344.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/741918
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 86
  • ???jsp.display-item.citation.isi??? 71
social impact